ActRII Inhibitor Polypeptides for CKD-MBD Bone and Vascular Calcification

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Chronic kidney disease-mineral and bone disorder (CKD-MBD) leads to bone abnormalities and vascular calcification due to disrupted mineral and hormone homeostasis, which existing treatments fail to effectively address, particularly in low turnover bone disorders and vascular calcification.

Innovation Solution

Administration of an ActRII inhibitor, specifically a polypeptide with sequences similar to SEQ ID NOs: 2, 3, 7, 12, 17, 20, 21, and 23, which inhibits Activin Receptor Type II (ActRII) to treat CKD-MBD, low turnover bone disorders, and vascular calcification by regulating bone turnover and mineralization.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing treatments are used for CKD-MBD, then general bone health is maintained, but low turnover bone disorders and vascular calcification are not effectively addressed

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidapplicability to specific bone disorders

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies inhibition of ActRII (opposite of activation) to treat bone disorders. By blocking the Activin-ActRII pathway that normally suppresses bone formation, the treatment promotes bone turnover and mineralization in low turnover bone disorders while preventing vascular calcification, achieving targeted therapeutic effects where general treatments failed.

Inventive Principle:

Principle #13The other way round (Inversion)

2Productivity

If bone turnover is increased to treat low turnover bone disorders, then bone formation improves, but risk of vascular calcification increases

Engineering Contradiction:

Improvebone formation rateVSAvoidvascular calcification risk

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The ActRII inhibitor serves as a selective mediator that modulates the Activin signaling pathway specifically in bone tissue. This targeted approach increases bone formation through osteoblast activation while the inhibitor's specificity prevents systemic effects that would lead to vascular calcification, decoupling the two previously linked outcomes.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If mineral and hormone homeostasis is disrupted in CKD-MBD, then bone abnormalities occur, but existing treatments cannot effectively correct the underlying imbalances

Engineering Contradiction:

Improvecorrection of mineral imbalancesVSAvoidcomplexity of treatment regimen

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent extracts and targets the specific Activin-ActRII signaling pathway that drives mineral and bone disorders in CKD-MBD. By isolating this particular molecular mechanism as the therapeutic target, the treatment directly corrects underlying mineral imbalances through pathway inhibition rather than requiring complex multi-component regimens to address multiple downstream effects.

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentEP3308796B1Activin-actrii antagonists and uses for treating bone and other disorders

Publication Date: 2021.07.14 CELGENE CORP

Figure 1
Figure 2
Figure 3

AI summary

This invention provides an ActRII inhibitor for use in a method for treating chronic kidney disease-mineral and bone disorder (CKD-MBD) in a subject, wherein said ActRII inhibitor is a polypeptide comprising an amino acid sequence selected from the group disclosed in the application.